Henry Lambert - Pure Bioscience CEO and Director

PUREDelisted Stock  USD 0.13  0.00  0.00%   

CEO

Mr. Henry R. Lambert is Chief Executive Officer, Director of the company. Mr. Lambert is an accomplished food industry and consumer products executive with broad management skills, including strategic planning and business development, gotomarket execution, business integration and food safety. He has over 35 years of food industry experience, having worked at such notable companies as Heublein Inc., RJ Reynolds, Nabisco, Inc. and Pinnacle Foods. Mr. Lambert has served on boards and as a member of various food industry associations, including the International Foodservice Manufacturers Association, Institute of Food Technologists and Safe Supply of Affordable Food Everywhere . From 2010 through June 2013, Mr. Lambert served as General Manager of the Global Food and Water Business of Underwriter Laboratories, where he was responsible for the startup of the companys food safety services business. From 2007 to 2010, Mr. Lambert served as Senior Vice President of Business Development, and then President, of Arrowstream Transportation, Inc., a provider of innovative supply chain management solutions to the foodservice industry whose key customers included Wendys, Applebees, Arbys, TGIF, Sysco, and DMA since 2017.
Age 66
Tenure 7 years
Professional MarksMBA
Phone619 596 8600
Webhttps://www.purebio.com
Lambert earned his MBA in Finance from the University of Chicago, Booth School of Business, and his BA in Economics from Union College, Schenectady, N.Y.

Pure Bioscience Management Efficiency

The company has return on total asset (ROA) of (0.6231) % which means that it has lost $0.6231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2879) %, meaning that it created substantial loss on money invested by shareholders. Pure Bioscience's management efficiency ratios could be used to measure how well Pure Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 239 K in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Pure Bioscience has a current ratio of 1.98, which is within standard range for the sector. Debt can assist Pure Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Pure Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pure Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pure to invest in growth at high rates of return. When we think about Pure Bioscience's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

CEO Age

Michael MBAChimerix
51
PoWen YenUnited Microelectronics
N/A
Mark DurcanMicron Technology
54
Michael ShermanChimerix
51
Ugur MDBioNTech SE
59
Michael AlrutzChimerix
54
Michelle BerreyChimerix
47
Bowen YanUnited Microelectronics
N/A
Leonard SchleiferRegeneron Pharmaceuticals
65
Manuel MDMustang Bio
70
Deyin LiuTaiwan Semiconductor Manufactur
N/A
Sanjay MehrotraMicron Technology
65
Zhejia WeiTaiwan Semiconductor Manufactur
N/A
Richard WallaceKLA Tencor
64
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people. Pure Bioscience [PURE] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Pure Bioscience is listed under Chemicals category by Fama And French industry classification.

Management Performance

Pure Bioscience Leadership Team

Elected by the shareholders, the Pure Bioscience's board of directors comprises two types of representatives: Pure Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pure. The board's role is to monitor Pure Bioscience's management team and ensure that shareholders' interests are well served. Pure Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pure Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Albert Beraldo, Director
Tom Myers, COO
Tom CPA, Pres CEO
Balbir Johal, Director
William Otis, Independent Director
David Pfanzelter, Independent Chairman of the Board
David Theno, Independent Director
Bhupender Gosain, CFO and Corporate Secretary
James Boyce, Director
Dale Okuno, Director
Geoff Balderson, CFO, Director
Henry Lambert, CEO and Director
Thomas Myers, COO Director
Jane Pagel, Director
John Kasperski, VP Sales
Malay Panchal, CEO, Director
Zhinong Yan, Exec Devel
Elisabeth Hagen, Independent Director
Eric Warren, Director
Chandrakant Panchal, Chairman of the Board
Ivan Chen, Independent Director
Tom Lee, Director
Janet Risi, Independent Director
Gary Cohee, Director
Brian ONeill, Director
Mark Elliott, Principal Financial and Accounting Officer and VP of Fin.
Erica Bearss, Independent Director

Pure Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Pure Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pure Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pure Bioscience's short interest history, or implied volatility extrapolated from Pure Bioscience options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pure Bioscience using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Consideration for investing in Pure OTC Stock

If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Directory
Find actively traded commodities issued by global exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA